Evidence map›Paper›PMID 36123650›Full record

ArticleMicrobial cell factories2022

An accurate strategy for pointing the key biocatalytic sites of bre2691A protein for modification of the brevilaterin from Brevibacillus laterosporus.

Panpan Han, Zhou Chen, Yangliu Liu, Aijin Ma, Siting Li, Yingmin Jia

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Panpan HanSchool of Food and Health, Beijing Technology and Business University, No.33 Fucheng Road, Haidian District, Beijing, 100048, China.
Zhou ChenSchool of Food and Health, Beijing Technology and Business University, No.33 Fucheng Road, Haidian District, Beijing, 100048, China.
Yangliu LiuSchool of Food and Health, Beijing Technology and Business University, No.33 Fucheng Road, Haidian District, Beijing, 100048, China.
Aijin MaSchool of Food and Health, Beijing Technology and Business University, No.33 Fucheng Road, Haidian District, Beijing, 100048, China.
Siting LiSchool of Food and Health, Beijing Technology and Business University, No.33 Fucheng Road, Haidian District, Beijing, 100048, China.
Yingmin JiaSchool of Food and Health, Beijing Technology and Business University, No.33 Fucheng Road, Haidian District, Beijing, 100048, China. jiayingmin@btbu.edu.cn.
Beijing Technology and Business University · CN

Funding

National Natural Science Foundations of China 31801510National Natural Science Foundations of China 32072199
6 · The paper itself

Abstract

backgroundBrevilaterin A-E, a novel class of multi-component cationic antimicrobial lipopeptides, were biosynthesized by a non-ribosomal peptides synthetase (NRPS) in Brevibacillus laterosporus. However, the antimicrobial abilities of different brevilaterin components varied greatly, and this multi-component form was impeding the scale production of the excellent component, and a little information about the brevilaterin biosynthesis mechanism was available to apply in brevilaterin design modification. In this study, we used an accurate strategy that revealed the reason for producing multi-component was the substrate selectivity of bre2691A protein being not enough specific and pinpointed the key design sites to make the specificity of bre2691A enhanced.

resultsBioinformatic analysis revealed that the biocatalytic site of bre2691A, which was an adenylation domain catalyzed and recognized methionine, leucine, valine and isoleucine and thus introduced them into brevilaterins and caused different components (brevilaterin A-E), was consisted of A1 ~ A10 residues named specificity-conferring code. Coupling molecular docking simulations with mutation studies identified A2 and A7 as critical residues, where determined substrate-specificity and impacted activity. The in virto activity assay showed that the A2 mutant (G193A) would lose activity against methionine and have no effect on the other three amino acids, the A7 mutant (G285C) would enhance the catalytic activity against four substrates, especially against leucine at almost a double activity. When the A2 and A7 residues were synchronously mutated, this mutant would be more focused on recognizing leucine.

conclusionsAn accurate strategy that combined with bioinformatics and site-directed mutation techniques revealed the pivotal site A2 and A7 positions of bre2691A protein that could be used to design and modify brevilaterins, thus further providing a reasonable direction of genetic engineering for Brevibacillus laterosporus. A deeper understanding of the function of crucial residues in the adenylation domain would make it get more accurate and highly efficient design and more fully utilized. Furthermore, it would contribute to biotechnological applications, namely for the large centralized synthesis of antimicrobial peptides, or for the optimization of their production.

Indexed as

Anti-Infective AgentsBacillusAmino AcidsAnti-Bacterial AgentsBacterial ProteinsBiocatalysisBrevibacillusIsoleucineLeucineLipopeptidesMethionineMolecular Docking SimulationValineAmino AcidsAnti-Bacterial AgentsAnti-Infective AgentsBacterial ProteinsIsoleucineLeucineLipopeptidesMethionineValineAdenylation domainBiocatalyticBrevibacillus laterosporusCationic antimicrobial peptide

Identifiers

PMID36123650
PMCPMC9484153
OpenAlexW4296348428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.